AGILE THERAPEUTICS INC Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q2 2019 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Agile Therapeutics Inc annual/quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q2 2019 to Q4 2022.
  • Agile Therapeutics Inc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending December 31, 2022 was -$3.93M, a 79.9% increase year-over-year.
  • Agile Therapeutics Inc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending December 31, 2022 was -$25.4M, a 64.2% increase year-over-year.
  • Agile Therapeutics Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$14.5M, a 43.1% increase from 2022.
  • Agile Therapeutics Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$25.4M, a 64.2% increase from 2021.
  • Agile Therapeutics Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$71.1M, a 37.1% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 -$25.4M -$3.93M +$15.6M +79.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$41M -$5.93M +$10.8M +64.6% Jul 1, 2022 Sep 30, 2022 10-K 2023-03-23
Q2 2022 -$51.9M -$5.17M +$12.5M +70.7% Apr 1, 2022 Jun 30, 2022 10-K 2023-03-23
Q1 2022 -$64.3M -$10.4M +$6.75M +39.4% Jan 1, 2022 Mar 31, 2022 10-K 2023-03-23
Q4 2021 -$71.1M -$19.5M -$1.9M -10.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-28
Q3 2021 -$69.2M -$16.8M -$1.25M -8.05% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$67.9M -$17.6M -$6.82M -63.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$61.1M -$17.1M -$9.25M -117% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$51.9M -$17.6M Oct 1, 2020 Dec 31, 2020 10-K 2023-03-23
Q3 2020 -$15.5M -$11.1M -250% Jul 1, 2020 Sep 30, 2020 10-Q/A 2021-12-30
Q2 2020 -$10.8M -$7.33M -210% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-26
Q1 2020 -$7.88M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q3 2019 -$4.43M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$3.48M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.